Liver transplantation for patients with colorectal cancer liver metastases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of a two-stage hepatectomy combined with living donor liver transplantation for patients with irresectable liver metastases from colorectal cancer. The approach aims to achieve a complete tumor removal (R0 situation) by first performing a right portal vein ligation followed by a left-lateral liver transplantation. The study is designed as a one-arm trial without a control group, comparing outcomes to historical data from patients receiving standard chemotherapy. The primary endpoint is overall patient survival 36 months after the second stage of the procedure.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with irresectable colorectal liver metastases without extrahepatic tumor burden, except resectable pulmonary metastases
* stable disease or regression after at least eight weeks of systemic chemotherapy

Exclusion Criteria:

* comorbidities precluding liver transplantation
* extrahepatic tumor spread, except resectable pulmonary metastases
* progression during chemotherapy

Where it's running

• Jena University Hospital
  Jena, Germany Recruiting
• University Hospital Tübingen
  Tübingen, Germany Recruiting

Study contacts

• Study coordinator: Falk Rauchfuss, M.D., M.Sc.
• Email: Falk.Rauchfuss@med.uni-jena.de
• Phone: 004936419322601

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Metastatic liver cancer patient registry from multiple Chinese centers

  This is a registry that collects real-world data on adults with liver metastases to understand patterns and prognosis and to support future research.

  Recruiting at 2 sites Anhui Provincial Hospital · Bengbu, Anhui and 2 other locations · NCT07602504

• Testing immunotherapy combinations for colorectal cancer that has spread to the liver

  This study is testing different combinations of immunotherapy treatments for people with colorectal cancer that has spread to the liver to see if they can improve treatment results before surgery.

  Recruiting Phase 2 Weill Medical College of Cornell University · New York, New York · NCT06300463

• Cryoablation with Sintilimab and Regorafenib for Liver Metastases from Colorectal Cancer

  This study is testing if combining a freezing treatment with two medications can help people with liver cancer from colorectal cancer who haven't responded to previous treatments.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT05057052

• Prospective look at liver metastases imaging and tissue patterns in colorectal and breast cancer

  This observational study tests whether 3D maps of histopathological growth patterns in liver metastases align with imaging features from MRI/CT in patients undergoing liver surgery.

  Recruiting Cancer Research Antwerp · Wilrijk, Antwerp · NCT07781306

• Predicting liver failure after major liver surgery using CT measurements and vascular shape changes

  Doctors are testing whether adding vascular deformation mapping to CT measurements can better predict liver failure after removing a large portion of the liver.

  Recruiting at 3 sites Minia University · Minya, Minya Governorate and 2 other locations · NCT07727759

• DRAGON: International registry for patients who had combined portal and hepatic vein embolization before liver surgery

  This registry collects data on patients who had PVE/HVE before liver resection to see if it helps liver regeneration and what factors relate to outcomes.

  Recruiting at 30 sites Maastricht University Medical Center · Chicago, Illinois and 30 other locations · NCT07717437

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.